View in EDS

5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.

Saved in:
Bibliographic Details
Title: 5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
Authors: Liu SV; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Babel RA; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Kao YH; Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Rahway, NJ, USA., Chirovsky D; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA., Namakydoust A; Oncology Clinical Development, Merck & Co., Inc., Rahway, NJ, USA., Velcheti V; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
Source: Immunotherapy [Immunotherapy] 2025 Oct; Vol. 17 (14), pp. 1005-1013. Date of Electronic Publication: 2025 Oct 17.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41104445
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Liu+SV%22">Liu SV</searchLink>; Department of Medical Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.<br /><searchLink fieldCode="AU" term="%22Babel+RA%22">Babel RA</searchLink>; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Kao+YH%22">Kao YH</searchLink>; Biostatistics and Research Decision Sciences (BARDS), Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Chirovsky+D%22">Chirovsky D</searchLink>; Value & Implementation Outcomes Research, Oncology, Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Namakydoust+A%22">Namakydoust A</searchLink>; Oncology Clinical Development, Merck & Co., Inc., Rahway, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Velcheti+V%22">Velcheti V</searchLink>; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101485158%22">Immunotherapy</searchLink> [Immunotherapy] 2025 Oct; Vol. 17 (14), pp. 1005-1013. <i>Date of Electronic Publication: </i>2025 Oct 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101485158 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1750-7448 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%221750743X%22">1750743X </searchLink><i>NLM ISO Abbreviation: </i>Immunotherapy <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41104445
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/1750743X.2025.2569856
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1005
    Titles:
      – TitleFull: 5-year real-world outcomes with first-line pembrolizumab plus chemotherapy in advanced/metastatic NSCLC.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Liu SV
      – PersonEntity:
          Name:
            NameFull: Babel RA
      – PersonEntity:
          Name:
            NameFull: Kao YH
      – PersonEntity:
          Name:
            NameFull: Chirovsky D
      – PersonEntity:
          Name:
            NameFull: Namakydoust A
      – PersonEntity:
          Name:
            NameFull: Velcheti V
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2025 Oct
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1750-7448
          Numbering:
            – Type: volume
              Value: 17
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Immunotherapy
              Type: main
ResultId 1